abstract |
The present invention includes humanized, chimeric and fully human antibodies against Wilms Tumor Protein (WT1), antigen binding proteins that specifically bind to WT1, antibody fragments thereof, chimeric antigen receptors (CARs), fusions Proteins, and conjugates. The antigen binding protein and antibody bind to HLA-A0201-limited WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof may be used for WT1-associated cancers such as breast cancer, ovarian cancer, prostate cancer, chronic myeloid leukemia, multiple myeloma, acute lymphocytic leukemia (ALL), acute myeloid / myeloid leukemia ( AML) and myelodysplastic syndromes (MDS). In more particular embodiments, the anti-WT1 / A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and / or expression levels. |